Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial
Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19.
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)
Adagio Therapeutics Announces Expansion Of Patient Population In Global Phase 2/3 Clinical Trial Of ADG20 For The Prevention of COVID-19
https://investors.adagiotx.com/news-releases/news-release-details/adagio-therapeutics-announces-expansion-patient-population
53 Biggest Movers From Friday
Gainers
Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 1)
Morgan Stanley Initiates Coverage On Adagio Therapeutics with Equal-Weight Rating, Announces Price Target of $33
Morgan Stanley analyst Matthew Harrison initiates coverage on Adagio Therapeutics (NASDAQ:ADGI) with a Equal-Weight rating and announces Price Target of $33.